# TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends

> **NCT07736846** · — · NOT_YET_RECRUITING · sponsor: **AOP Orphan Pharmaceuticals AG** · enrollment: 300 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)

## Interventions

- **DRUG:** treprostinil

## Key facts

- **NCT ID:** NCT07736846
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-12
- **Final completion:** 2031-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07736846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07736846, "TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07736846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*